Shares of Torrent Pharmaceuticals hit a 52-week high in early trade as brokerages cheered in-line Q1FY26 results. Its net profit increased 20 per cent y-o-y to ₹548 crore for the quarter under review.
Citi has maintained buy at an increased target price of ₹4,380 from ₹4,000 earlier. The brokerage expects margin expansion to continue due to operating leverage in branded segments and potential US recovery.
Nuvama Institutional Equities argued that the pharma’s India business would benefit over the medium term due to the addition of 1,200 medical representatives (MRs) over FY25 and FY26. JB Chemicals’ acquisition is a long-term growth or value driver. Nuvama remains optimistic on Torrent Pharma and retained buy at an increased target price from ₹3,920 earlier to ₹4,180.
Elara Capital upgraded the stock from reduce to accumulate rating at a target price raised from ₹3,382 to ₹4,048 per share. However, it flagged slowdown in domestic market as a key risk.
HDFC Securities believes Torrent Pharma is well-positioned for steady growth, driven by its strong branded franchise supported by new product launches, expanding consumer wellness portfolio, and continued momentum in Brazil and a gradual turnaround in the US generics. The analysts retained add rating at a revised target price of ₹3,780 per share.
InCred Equities — maintaining hold at new target price of ₹3,700 per share — observed that at the current valuation, the stock is priced to perfection, reflecting strong fundamentals, growth outlook and concerns regarding acquisition. The valuation is likely to remain buoyant, supported by healthy earnings growth and continued operational excellence, it added.
At 11 am, the stock surged 3.03 per cent to ₹3,734.45 on the BSE after hitting a 52-week high of ₹3,749 in early trade.
More Like This
Published on July 29, 2025
